Journal
MAYO CLINIC PROCEEDINGS
Volume 80, Issue 8, Pages 1029-1036Publisher
MAYO CLINIC PROCEEDINGS
DOI: 10.4065/80.8.1029
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL36634] Funding Source: Medline
Ask authors/readers for more resources
Cardiac secretion of B-type natriuretic peptide (BNP) Increases with the progression of heart failure (HF), and plasma measurement of BNP has emerged recently as a useful, cost-effective blomarker for the diagnosis and prognosis of HF. The diagnostic utility of BNP Is complemented by Its therapeutic use In decompensated HF. Although clinical use of BNP as a blomarker In HF Is Increasing, the specificity of BNP for HF Is not robust, suggesting that other mechanisms beyond simple ventricular stretch stimulate BNP release. Several studies have shown that BNP levels Increase In other cardiovascular disease states Including Ischemia, arrhythmias, fibrosis, cardiac hypertrophy, and coronary endothelial dysfunction. Furthermore, 2 Important studies revealed recently that moderate elevations In BNP level, well below the HF range, have prognostic value for future cardiovascular events. Specifically, BNP levels greater than 20 pg/mL were associated with significantly Increased risk of HF and atrial fibriliation. These observations Increase speculation that elevated BNP levels represent a final common pathway for many cardiovascular pathologic states and that BNP can be used as a blomarker for non-HF mechanisms, preclinical disease, and other pathologic states of myocardial disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available